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  Abstract 
  Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to 
acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target 
for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are 
aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads 
to a signiﬁ  cant reduction of non-fatal myocardial infarction (–32%), non-fatal stroke (–25%), and of cardiovascular death 
(–17%), a residual risk persists.     
  Newer antiplatelet agents have addressed some, but not all, these limitations. Vis-  à  -vis their net clinical beneﬁ  t, the 
higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do 
not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into considera-
tion clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. 
The well-established road signs of clinical epidemiology will provide major information to deﬁ  ne newer potentially useful 
targets for platelet pharmacology.     
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              Introduction 
  Thrombotic (ischemic) complications of atheroscle-
rosis (acute coronary syndrome (ACS), acute myo-
cardial infarction (AMI), ischemic stroke) are the 
leading causes of morbidity and mortality in Western 
countries. Following atherosclerotic plaque disrup-
tion/endothelial cell detachment, circulating platelets, 
exposed to a highly thrombogenic environment, 
become activated (1). As shown in Table I, a series of 
soluble agonists (ADP, thromboxane A  2   (TxA  2  ), 
serotonin (5-HT), and thrombin) recruit and activate 
additional platelets (2,3). Upon activation, glycopro-
tein (Gp) IIb/IIIa (  α    IIb    β    3   integrin) mediates platelet 
aggregation and spreading by means of ﬁ  brinogen 
bridges, which, once converted to ﬁ  brin, ultimately 
contribute to thrombus stabilization (4). This leads 
to the formation of platelet-rich thrombi that, occlud-
ing the arterial lumen and impairing blood-ﬂ  ow and 
oxygen supply, cause acute ischemia (5). 
  The transduction of the ADP signal involves its 
interaction with two platelet receptors belonging to 
the P  2   purinergic family, the G  α  q-coupled receptor 
P  2  Y  1   and the G  α  i-coupled receptor P  2  Y  12  . The con-
comitant activation of both the G  α  q and G  α  i path-
ways by ADP is needed for platelet aggregation 
to occur. Signaling from the P  2  Y  1   receptor causes 
platelet shape change and rapid transient aggrega-
tion, whereas the signaling from the P  2  Y  12   receptor 
facilitates sustained irreversible aggregation and 
stimulates surface expression of the pro-inﬂ  ammatory 
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P-selectin (6). In addition, the P  2  Y  12   receptor 
plays a critical role in the ampliﬁ  cation of platelet 
aggregation induced by agents other than ADP, 
including 5-HT, TxA 2  , and thrombin. Together, these 
contri  bute to thrombus growth and stability (5). 
      TxA  2  , generated from arachidonic acid by cyclo-
oxygenase 1 (COX-1) and Tx synthase, further 
ampliﬁ  es platelet activation. COX-1 converts arachi-
donic acid into prostaglandin endoperoxides PGG  2   
and PGH  2  , the latter being, in turn, transformed by 
Tx synthase into TxA  2  , a potent ampliﬁ  er of platelet 
aggregation with vasoconstrictive properties. At the 
site of the atheroma rupture, platelet-released TxA  2   
leads to downstream micro-vessel contraction and 
thrombus propagation (7). 
  In addition to its role in coagulation, thrombin 
at extremely low concentrations is one of the major 
platelet activators (8). Human platelets express two 
cell surface G-protein-coupled protease-activated 
receptors (PARs) for thrombin: PAR-1 and PAR-4. 
By binding the hirudin-like extracellular amino ter-
minal domain (the so-called thrombin receptor), 
thrombin activates platelets and smooth muscle cells, 
thus promoting platelet pro-coagulant activity, shape 
change, secretion and release of agonists (ADP and 
TxA  2  ), expression of P-selectin, activation of the 
  α    IIb    β    3   integrin receptor, and aggregation. Thrombin 
also binds to GpIb   α    on the surface of platelets, 
thought to act as a co-factor that localizes the enzyme 
on the platelet surface and accelerates the hydrolysis 
of PAR-1 (9). PAR-1 and P  2  Y  12   cross-react in plate-
let activation, and G  α  q and G  α  i-coupled receptors 
are involved in this process. Thrombin-dependent 
platelet aggregation is mediated in part by secreted 
ADP, acting on the G  α  i-linked ADP receptor. By 
blocking G  α  q via PAR-1 and G  α  i via P  2  Y  12  , combined 
inhibition of thrombin and P  2  Y  12   receptors leads to 
a synergistic inhibitory effect on thrombin-induced 
platelet aggregation (10). 
  5-HT is a vasoconstrictor agent that binds to 
5HT-2A receptors and ampliﬁ  es the platelet response 
by stimulating shape change and enhancing platelet 
recruitment at sites of injury (3). It may also play 
a pro-coagulant role by promoting the retention 
of ﬁ  brinogen and thrombospondin on the platelet 
surface. Intraplatelet 5-HT stores are implicated 
in shear-induced platelet aggregation and thrombus 
propagation (3).     
  Antiplatelet agents in clinical practice: 
efﬁ  cacy, safety, limitations (Figure 1) 
  Three main classes of antiplatelet agents are licensed 
for treatment of atherothrombosis: acetyl salicylic 
acid (aspirin), P  2  Y  12   inhibitors (ticlopidine, clopi-
dogrel, prasugrel, cangrelor, ticagrelor), and GpIIb/
IIIa receptor antagonists (abciximab, eptiﬁ  batide, 
and tiroﬁ   ban) (11). While the last-mentioned are 
only employed intravenously in ACS in combination 
with other antithrombotic agents (their effect being 
rather unpredictable when administered orally), the 
former two classes are widely used chronically.   
  Aspirin 
  Owing to its efﬁ  cacy and favorable cost-effectiveness, 
aspirin is the mainstay treatment for all atherothro-
mbotic conditions. The efﬁ  cacy of aspirin lies in its 
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    Table I. Platelet activation: agonists and signal transduction.   
Agonist Receptor(s) Effect(s) Comments
ADP Gaq-coupled  P  2  Y  1  ;  
Gai-coupled P  2  Y  12 
P  2  Y  1  : shape change; P  2  Y  12  : 
aggregation
P  2  Y  12   ampliﬁ  es aggregation induced 
by 5-HT, TxA  2  , and thrombin
TxA  2  TPa; TPb (secondary) Shape change; platelet recruitment; 
platelet aggregation
In endothelial cells, COX-1-derived 
PGH  2   is converted into PGI  2  , 
a strong antiaggregating and 
vasodilating agent
Thrombin PAR-1; PAR-4 (secondary); 
GpIb   α  
Shape change; ADP and TxA  2   
secretion; P-selectin expression; 
  α    IIb    β    3   integrin receptor; platelet 
activation
PAR-1 and P  2  Y  12,   cross-reaction (via 
G  α  q and G  α  i-coupled receptors)
Serotonin 5HT-2A receptors Shape change; platelet recruitment; 
retention of ﬁ  brinogen and 
thrombospondin on the 
platelet surface
Implicated in shear-induced platelet 
aggregation and thrombus 
propagation      New antiplatelet drugs       533
ability to inhibit irreversibly platelet COX-1 (by acety-
lating a serine located near the active site of the enzyme) 
and, in turn, TxA  2   formation (12). A recent meta-
analysis by the Antithrombotic Trialists  ’   Collabora-
tion (13) assessed the role of aspirin in primary (95,000 
subjects at low cardiovascular risk) and secondary 
prevention (17,000 patients at medium/high risk) 
and showed that, while in high-risk conditions the 
advantages of aspirin outweigh the inherent bleeding 
hazard, in primary prevention aspirin is associated with 
an absolute beneﬁ  t of 0.06%/year, too exiguous as 
compared to the 0.03% increase in major bleedings.     
  Ticlopidine 
  Ticlopidine was the ﬁ  rst agent of the thienopyridine 
class shown both to prevent the interaction of ADP 
with its platelet purinergic receptor and to determine 
the inhibition of the binding of ﬁ   brinogen to the 
  α    IIb    β    3   integrin (14). In subjects with a history of 
cerebrovascular events, ticlopidine was superior to 
placebo and to aspirin in the reduction of stroke, 
AMI, or vascular death (15). In addition, the com-
bination of ticlopidine with aspirin was successful 
in ACS patients undergoing percutaneous coronary 
intervention (PCI) with stent implantation (16). 
Diarrhea, neutropenia, aplastic anemia, and throm-
botic thrombocytopenic purpura are the main 
limitations for a wide-spread use of ticlopidine.     
  Clopidogrel 
  The thienopyridine prodrug clopidogrel irreversibly 
binds the P  2  Y  12   platelet receptor after a two-step 
activation by cytochrome P450 (CYP) liver isoen-
zymes. While the CAPRIE trial (about 20,000 sub-
jects) (17) and a Cochrane systematic review (18) 
showed that in patients with a history of AMI, stroke, 
or symptomatic peripheral arterial disease (PAD), 
clopidogrel administered alone was only marginally 
superior to aspirin (RRR 8.7;   P       0.043) in prevent-
ing vascular events, a signiﬁ  cantly higher efﬁ  cacy has 
been shown for the   ‘  dual antiplatelet therapy  ’  . The 
CURE (19) and the CREDO (20) studies estab-
lished the superiority of clopidogrel in combination 
with aspirin versus aspirin alone in ACS and in ACS 
with PCI, respectively.       
  Low response to aspirin or clopidogrel 
  Although antiplatelet treatment in high-risk patients 
signiﬁ  cantly lowers non-fatal AMI (32%), non-fatal 
    Figure 1.             Platelet activation pathways and drug molecular targets. Thrombin binds to PAR-1 receptor, which leads to shape change, 
phospholipase C (PLC) activation, thromboxane A2 (TXA2) generation, and activation of the glycoprotein (GP) IIb/IIIa receptor, 
resulting in sustained platelet aggregation. Cyclooxygenase (COX)-1 catalyzes the production of TXA2, a potent platelet aggregator, 
generated by platelets activated by thrombin and other agonists. Adenosine 5′-diphosphate (ADP) binds to its 7-transmembrane domain 
receptors, P2Y1 and P2Y12, to activate platelets. P2Y1 is coupled to Gαq and G12. Gαq is linked to a signaling pathway involving PLC 
activation, resulting in a rise in the intracellular calcium concentration ([Ca2]i) and protein kinase C (PKC) activation, leading to GP 
IIb/IIIa activation and transient platelet aggregation. G12 mediates platelet shape change. P2Y12 is linked to Gαi-coupled signaling 
cascades associated with adenylcyclase (Ac) down-regulation and decreased cyclic-3′,5′-monophosphate (cAMP) production, which 
mediates GP IIb/IIIa receptor activation, leading to sustained platelet aggregation.534     M. N. D. Di Minno et al.     
stroke (25%), and cardiovascular death (17%), a 
residual vascular risk persists. After an AMI or a 
stroke, in a long-term follow-up, 10%  –  20% of patients 
with a history of an ischemic event develop recurrent 
events in spite of their antiplatelet treatment (21). 
Compared to aspirin-sensitive patients, the residual 
platelet reactivity in subjects on antiplatelet therapy 
correlates with a higher cardiovascular risk and pre-
dicts recurrent thrombotic events (22). In the HOPE 
study, aspirin-treated patients in the highest quartile 
of the urinary excretion of TxA  2   metabolite had a 
1.8-fold higher vascular risk than those in the lowest 
quartiles (23). A meta-analysis (24) evaluated the 
relation between a low laboratory response to clopi-
dogrel and the clinical outcome in   ≈  4,500 patients 
with coronary artery disease (CAD) and PCI. Several 
methods were used to assess platelet response to 
therapy, and 26.4% of patients showed as low respond-
ers to clopidogrel. These patients showed a higher risk 
of death/ischemic events as compared to that of patients 
in whom a normal response was documented. 
  Although often secondary to a poor compliance 
(25), a low treatment response (  ‘  failure  ’  ) may be due, 
at least in part, to an incomplete inhibition of platelet 
function (26). Concomitant clinical conditions (dia-
betes mellitus, inﬂ  ammation, hypercoagulable states, 
low ﬁ  brinolytic potential), high pretreatment platelet 
reactivity (observed in ACS or in subjects with high 
BMI), an increased platelet turn-over, and the simul-
taneous administration of some drugs (drug interac-
tion and/or inadequate drug absorption) are common, 
major determinants of a low response to clopidogrel 
or to aspirin (21,27). The possibility that, in addition 
to such conditions, genetic variations play a role in a 
low response to aspirin or to clopidogrel has also 
been documented. Different haplotypes of COX-1 
signiﬁ   cantly correlate with the response to aspirin 
and with TxA  2   generation in patients with stable 
coronary artery disease (28). 
  A variety of polymorphisms in the CYP2C19 
gene (most often the CYP2C19  ∗  2), associated with 
a 20%  –  25% production of inactive metabolite, 
diminish the response to clopidogrel. Among sub-
jects under treatment with clopidogrel for a previous 
vascular event, carriers of these polymorphisms have 
a 50% higher risk of cardiovascular death, AMI, or 
stroke (29). Among clopidogrel-treated patients, 
carriers of at least one allele associated with the loss 
of or a reduced function in the CYP2C19 gene had 
a higher than normal occurrence of fatal and non-
fatal coronary thrombotic events, as well as of stent 
thrombosis (29). In the same study population, 
polymorphic alleles of a gene modulating clopi-
dogrel absorption (ABCB1) have been associated 
with a higher rate of cardiovascular events at 1-year 
follow-up as compared to wild-type subjects.     
  Overcoming limitations of aspirin   
  Changing doses and schedules of aspirin 
  Because inhibition of platelet aggregation by aspirin 
is irreversible, the possibility of monitoring the entry 
of newly formed platelets into the circulation (i.e. the 
platelet turn-over) was documented by measuring 
the recovery of TxB  2   biosynthesis after aspirin inges-
tion (30). The data show that platelets with intact 
cyclo-oxygenase activity can be detected into the cir-
culation as early as 4  –  6 h after aspirin ingestion. 
A higher than normal rate of entry of platelets into 
the circulation has been documented in diabetic 
angiopathy or in patients with coronary artery 
bypass (31). Indeed, schedules of aspirin which may 
sufﬁ  ce in normal subjects are not effective in patients 
with diabetic angiopathy, presumably because these 
patients have a high rate of entry of new platelets 
into the circulation (27). A long-lasting suppression 
of thromboxane biosynthesis may be achieved by 
repeated low-dose administrations or by slow-release 
preparations of aspirin. The relevance of an acceler-
ated platelet turn-over as to   ‘  aspirin resistance  ’   has 
been conﬁ  rmed in a series of clinical settings (32,33). 
  Attempts to improve the efﬁ  cacy of aspirin by 
using larger doses have been associated with con-
trasting results (34). Moreover, a signiﬁ  cant higher 
bleeding risk (mainly gastrointestinal) may occur 
with higher aspirin doses. Thus, increasing the dose 
of aspirin would expose the patient to a doubtful 
clinical advantage (35).       
  Overcoming limitations of clopidogrel   
  Changing doses of clopidogrel 
  In spite of the greater antithrombotic efﬁ  cacy  of 
higher doses of clopidogrel, thrombotic events still 
occur in 4.2% of patients (36). 
  Whereas a vasodilator-stimulated phosphoprotein 
(VASP)-tailored clopidogrel loading dose has been 
found to improve the clinical outcome (37) and to 
reduce the rate of early stent thrombosis after PCI 
(38), the GRAVITAS trial has been designed to evalu-
ate only the efﬁ  cacy and safety of VASP-tailored clopi-
dogrel-maintaining regimens (39). Early results of the 
study indicate that, compared with standard-dose, 
high-dose clopidogrel only achieved a modest pharma-
codynamic effect in PCI patients with high residual 
platelet activity. Moreover, 6-month higher-dose clopi-
dogrel did not reduce the rate of cardiovascular death, 
non-fatal MI, or stent thrombosis, nor did it increase 
severe or moderate bleeding. Thus the GRAVITAS 
study does not support a treatment strategy of high 
clopidogrel dose in PCI patients with high residual 
activity, identiﬁ  ed by a single platelet function test.       New antiplatelet drugs       535
  Further strategies have been evaluated to over-
come clopidogrel limitations.   Ω  -3 Ethyl esters (1 g/day 
for 1 month) added to standard dual antiplatelet 
therapy signiﬁ  cantly lowered maximal platelet aggre-
gation in response to ADP and VASP phosphorylation 
as well (40). 
  Cilostazol, selectively targeting phosphodiesterase 
type 3 (PDE3) and, then, determining intracellular 
cAMP accumulation, inhibits platelet aggregation 
(41). In diabetic patients on standard dual antiplatelet 
therapy, adjunctive treatment with cilostazol enhances 
inhibition of platelet P  2  Y  12   signaling (42). A Cochrane 
review (43), in which two randomized studies on 
stroke prevention were summarized, documented 
that, compared with aspirin, cilostazol was associated 
with a signiﬁ   cantly lower risk of vascular events 
(6.77% versus 9.39%; RR 0.72; 95% CI 0.57  –  0.91, 
composite outcome), and with a lower risk of hemor-
rhagic stroke (0.53% versus 2.01%; RR 0.26; 95% 
CI 0.13  –  0.55). In terms of outcome of safety, cilostazol 
was associated with signiﬁ  cantly fewer adverse events 
(8.22% versus 4.95%; RR 1.66; 95% CI 1.51  –  1.83) 
than aspirin. In the SILOAM phase IV study (Clini-
calTrials.gov Identiﬁ   er: NCT01261832), a triple 
antiplatelet therapy (cilostazol plus aspirin and clopi-
dogrel) is compared (at 1 month and at 6 months) 
with the standard dual antiplatelet treatment (ASA 
and clopidogrel) in 951 ACS subjects (expected 
number) undergoing PCI and drug eluting-stent 
implantation. The primary efﬁ  cacy end-point is the 
occurrence of major cardiovascular and cerebrovascu-
lar events (total death, non-fatal myocardial infarc-
tion, repeat revascularization, stroke). The end of the 
study is expected by January 2013.       
  Exploring newer antiplatelet strategies 
(Table II)   
  Prasugrel 
  Prasugrel, a prodrug of the thienopyridine family, 
after a rapid one-step conversion into a highly 
bioavailable metabolite, causes an irreversible block 
of the P2Y12 ADP receptor. Because of a distinct 
chemical structure, the conversion to its active 
metabolite is less dependent on speciﬁ  c cytochrome 
P450 enzymes than that of other thienopyridines 
(44). A phase I study (45) evaluated the inhibition 
of ADP-induced platelet aggregation by prasugrel 
(60 mg loading and 10 mg repeated doses) as com-
pared to clopidogrel (300 mg loading dose and 75 
mg repeated doses). In platelets exposed to ADP, 
inhibition of the aggregation and the onset of the 
antiplatelet effect were higher for prasugrel than for 
clopidogrel (maximal inhibition achieved 30  –  60 min 
and 4  –  6 hours after prasugrel and clopidogrel, 
    Table II. Molecular targets of newer and emerging antiplatelet therapies.   
Drug Mechanism Comment
Prasugrel P  2  Y  12   receptor inhibition Irreversible inhibition; orally active
Cangrelor Adenosine triphosphate analog with a high afﬁ  nity 
for the P  2  Y  12   receptor
Reversible inhibition; intravenous
Ticagrelor P  2  Y  12   and (partly) P  2  Y  1   receptor inhibition Reversible inhibition; orally active
Elinogrel P  2  Y  12   receptor inhibition Reversible; oral and intravenous
Vorapaxar 
(E530348)
PAR-1 inhibitor No effect on thrombin-induced ﬁ  brin production, 
orally active
Atopaxar (E5555) Low-molecular-weight PAR-1 inhibitor Inhibition of expression of the inﬂ  ammatory markers 
(sCD40L and interleukin 6 and the expression 
of P-selectin), orally active
Sarpogrelate Selective inhibitor of serotonin (5HT-2A) platelet 
receptors
Orally active
DZ-697b Inhibits collagen and ristocetin-mediated platelet 
adhesion and aggregation
Orally active
Gas6 (growth 
arrest-speciﬁ  c 
gene 6)
Vitamin K-dependent protein; a polyclonal 
anti-Gas6 antibody lowers platelet 
thromboembolism induced by the intravenous 
injection of collagen plus epinephrine and 
aggregation by ADP
Stored in platelet   α   granules, released upon activation. 
Through its carboxy-terminal domains it interacts with 
the membrane receptor tyrosine kinases (RTKs) of the 
TAM family (Tyro3, Axl, MerTK); through its vitamin 
K-dependent Gla module it interacts with 
phosphatidylserine-containing membranes
Matrix 
metalloproteinases 
(MMPs)
By potentiating PI3K activation, MMP-2 
ampliﬁ  es platelet aggregation regardless of the 
presence of aspirin and of P  2  Y  12   receptor 
antagonists
Involved in tissue remodeling and in the progression of 
atherosclerosis, MMP-2 is present in platelet cytosol 
and released upon aggregation
CD40 ligand 
(CD40L; CD154)
On activated platelets an exodomain (soluble 
CD40 ligand, sCD40L) is released and binds to 
  α    IIb    β    3   integrin, thus promoting thrombus 
stabilization and blunting platelet reactivity
Transmembrane protein expressed on the surface of 
activated platelets. Shedding of sCD40L from the 
surface of activated platelets can be prevented 
by an anti-CD40L antibody (G28-5)536     M. N. D. Di Minno et al.     
respectively). Of interest, the number of   ‘  non-
responders  ’   was signiﬁ   cantly lower with a 60-mg 
loading dose of prasugrel than with a 300-mg 
loading dose of clopidogrel (0% versus 42%). 
  A phase II dose-ranging trial, the JUMBO-TIMI 
26 (46), compared clopidogrel and prasugrel regi-
mens in 900 patients undergoing elective or urgent 
PCI plus stenting. Patients were randomized to one 
of three combinations of prasugrel loading and 
maintenance doses: 40 mg and 7.5 mg/d, 60 mg and 
10 mg/d, and 60 mg and 15 mg/d, or to the standard 
clopidogrel regimen (300 mg and 75 mg/d). While 
the thrombolysis in myocardial infarction (TIMI) 
major bleeding was similar between prasugrel and 
clopidogrel groups, subjects receiving prasugrel 
showed a lower incidence of the composite end-
point of 30-day major adverse cardiac events. Like-
wise, signiﬁ   cantly lower rates of coronary target 
vessel thrombosis were seen in prasugrel-treated 
patients. The PRINCIPLE-TIMI 44 (47) was a ran-
domized, double-blind, two-phase cross-over trial of 
prasugrel compared with high-dose clopidogrel in 
201 patients undergoing a planned PCI. In the ﬁ  rst 
phase, a 60-mg prasugrel loading dose was com-
pared with a 600-mg loading dose of clopidogrel. 
After the loading dose, the subjects received prasu-
grel 10 mg or clopidogrel 150 mg for 14 days, and 
then they were crossed over to the alternative treat-
ment for an additional 14 days. The primary end-
point was the inhibition of platelet aggregation at 
6 hours following 20   μ  mol/L ADP. After the loading 
dose, the inhibition of platelet aggregation at 6 hours 
was signiﬁ   cantly greater in the patients receiving 
prasugrel than in those on clopidogrel. In addition, 
patients on prasugrel showed more consistent levels 
of platelet inhibition, a lower interindividual vari-
ability, and a reduced incidence of low response as 
compared to those on clopidogrel. The same ﬁ  gures 
were conﬁ  rmed after 14 days of maintenance ther-
apy. Thus, both the 60 mg loading dose and the 
maintenance dose of 10 mg of prasugrel were supe-
rior to clopidogrel regimen in inhibiting P  2  Y  12  -
dependent platelet aggregation. As to safety ﬁ  ndings, 
no TIMI major bleeding event occurred after the 
loading dose in either group, whereas two subjects 
(2.0%) in the prasugrel group and no subject in 
the clopidogrel group experienced a TIMI minor 
bleeding episode before the cross-over. 
  The TRITON-TIMI 38 (48) was a randomized, 
double-blind, parallel-group, multinational phase III 
trial comparing the efﬁ  cacy and safety of prasugrel 
and clopidogrel in 13,608 subjects with ACS under-
going PCI and coronary stenting. Patients were 
randomized to receive prasugrel (60-mg loading 
dose followed by a 10-mg/day maintenance dose) 
or clopidogrel (300-mg loading dose followed by 
a 75-mg/day maintenance dose) for a mean of 
14.5 months. The primary efﬁ  cacy end-point (death 
from CV causes, non-fatal MI, non-fatal stroke) 
occurred in 643 patients (9.9%) receiving prasugrel 
and in 781 patients (12.1%) receiving clopidogrel 
(hazard ratio (HR) 0.81; 95% CI 0.73  –  0.90; 
  P       0.001). An early signiﬁ  cant difference in the pri-
mary end-point was also documented at the 3-day pre-
speciﬁ  ed time point, a ﬁ  nding consistent with a more 
rapid onset of the antiplatelet activity of prasugrel 
    Table III. Efﬁ  cacy and safety of newer antiplatelet drugs. Results from phase III studies.   
Study (ref)
TRITON-TIMI 38 (48), 13,608 subjects:
Study design Prasugrel (60-mg loading dose (LD)     10-mg maintenance dose (MD) versus 
Clopidogrel (300 mg LD     75 mg MD)
Efﬁ  cacy end-point 9.9% versus 12.1%;   P       0.001
Safety end-point 2.4% versus 1.8%;   P       0.03
CHAMPION-PCI (52), 8,887 subjects:
Study design Cangrelor (bolus 30   μ  g/kg      infusion 4   μ  g/kg/min)      Clopidogrel (600 mg LD) 
versus Placebo        Clopidogrel (600 mg LD)
Efﬁ  cacy end-point 7.5% versus 7.9%;   P       0.59
Safety end-point 0.4% versus 0.3%;   P       0.39
CHAMPION-PLATFORM (53), 2,654 subjects:
Study design Cangrelor (bolus 30   μ  g/kg or 4   μ  g/kg/min infusion for       2  h)     Clopidogrel 
(600 mg LD) versus Placebo        Clopidogrel (600 mg LD)
Efﬁ  cacy end-point 7.0% versus 8.0%;   P       0.17
Safety end-point 3.5% versus 5.5%;   P       0.001
The PLATO trial (53), 18,624 subjects:
Study design Ticagrelor (180 mg LD        90 mg twice a day MD) or Clopidogrel (300  –  600 mg 
LD      75 mg MD)
Efﬁ  cacy end-point 9.8% versus 11.7%;   P       0.001
Safety end-point 11.6% versus 11.2%;   P       0.46
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(43). Such difference was maintained from the third 
day to the end of the study. The difference in the 
primary end-point was found both among patients 
with unstable angina and non-STEMI and STEMI 
subjects, the reduction in AMI being the major deter-
minant of such difference. In addition, regardless of 
the type of stent, a signiﬁ  cant 52% reduction of stent 
thrombosis was found in the prasugrel group (49). 
  Vis-  à  -vis a 2.2% reduction in fatal and non-fatal 
ischemic events, both TIMI major and minor bleed-
ing episodes were 1.2% more frequent with prasug-
rel than with clopidogrel. The TIMI major bleeding 
was observed in 2.4% of subjects in the prasugrel 
group and in 1.8% in the clopidogrel group. The rate 
of life-threatening bleeding (1.4% versus 0.9%; 
  P        0.01) and of fatal bleeding (0.4% versus 0.1%; 
  P        0.002) was greater in the prasugrel group than 
in the clopidogrel group, with maximal bleeding 
risk in patients with a history of stroke/TIA (in 
whom this drug should be avoided, being associated 
with increased intracranial hemorrhage), in elderly 
patients (aged      75 years) and in those with a body-
weight      60 kg. On the other hand, based on TIMI 
major bleedings (key safety end-point of the trial), 
prasugrel should also be used with caution in candi-
dates to Coronary Artery Bypass Graft (CABG), 
      50% of total bleedings being reported in this set-
ting. Together, in a risk/beneﬁ   t analysis, prasugrel 
was 13% better than clopidogrel (HR 0.87; 95% CI 
0.79  –  0.95;   P       0.004), maximal clinical beneﬁ  t being 
found in patients with diabetes, with coronary stents, 
or with recurrent events (RRR 30%). Whether pra-
sugrel is safer and better than clopidogrel in reduc-
ing the risk of cardiovascular death, MI, or stroke, 
in patients with ACS who are medically managed, 
and in whom no revascularization is planned, will be 
evaluated in the TRILOGY ACS study, a phase III 
multicenter, double-blind, randomized, controlled 
trial including approximately 10,000 patients (50).     
  Cangrelor 
  Cangrelor, an adenosine triphosphate (ATP) analog 
with a high afﬁ  nity for the P  2  Y  12   receptor (35), does 
not need conversion, being immediately active fol-
lowing infusion (half-life of 3  –  6 min). In the STEP-
AMI trial, 92 ACS patients (51) treated with aspirin 
and heparin were randomized to receive cangrelor 
(280   μ  g/kg/min) alone, full-dose tissue plasminogen 
activator (t-PA) alone, or cangrelor (35, 140, or 
280   μ  g/kg/min) in combination with half-dose t-PA. 
A 60-min coronary patency similar to that of full-dose 
t-PA alone and a greater patency than with cangrelor 
alone was found in patients receiving the combina-
tion of cangrelor and half-dose t-PA. Although in 
two randomized controlled clinical phase III trials 
on ACS patients requiring PCI (CHAMPION PCI, 
CHAMPION PLATFORM) (52,53), cangrelor did 
not show superiority over clopidogrel, this drug is 
currently investigated as a bridge to CABG surgery 
(ClinicalTrials.gov Identiﬁ  er: NCT00767507).     
  Ticagrelor 
  Ticagrelor, an orally active cyclopentyl-triazolo-
pyrimidine, binds to domains of the P  2  Y  12   receptor 
other than those recognized by ADP (the 1, 2, 
and 7 transmembrane domains, the extracellular 
loop 2, and the N-terminal domain), determining 
a potent and rapid non-persistent receptor confor-
mational change. After the occupancy of P  2  Y  12  , 
ADP-catalyzed conversion of cAMP from ATP, 
dephosphorylation of phosphorylated VASP, and 
activation of phosphoinositide 3-kinase are blocked. 
The net result is a reduced exposure of ﬁ  brinogen-
binding sites on the   α    IIb    β    3   integrin receptor and, in 
turn, the inhibition of platelet aggregation. Inhibi-
tion of ADP-mediated constriction of vascular 
smooth muscle and enhancement of adenosine-
induced coronary blood-ﬂ  ow are also reported. After 
oral administration, ticagrelor is rapidly absorbed 
and does not require hepatic biotransformation 
to be pharmacologically active. However, ticagrelor 
is also metabolized to an equipotent, active metabo-
lite (AR-C124910XX) by CYP  3  A  4   enzymes. Being 
both ticagrelor and AR-C124910XX-excreted by 
the intestinal route, no dose adjustment is needed 
in kidney failure. On the other hand, the concomi-
tant use of CYP  3  A  4   inhibitors/inducers as well as a 
signiﬁ  cant liver dysfunction may be of concern for 
its use (54). After pharmacodynamic evaluations 
(55,56), a 90-mg twice daily dose of ticagrelor 
has been chosen to optimize its efﬁ  cacy, safety, and 
tolerability. A loading dose of 180  –  270 mg may 
minimize intersubject variability as to initial inhibi-
tion in platelet aggregation and may be appro-
priate in ticagrelor-naive patients with ACS or in 
preparation for PCI. 
  In 174 subjects with a recent coronary artery 
disease receiving 75  –  100 mg/day aspirin (92 also 
under ticagrelor 180-mg load and 90 mg/twice daily 
maintenance dose, and 82 also under clopidogrel 
600-mg load and 75 mg/d maintenance dose) the 
genotyping of the cytochrome P450 (CYP) 2C19 
(  ∗  1,  ∗  2,  ∗  3,  ∗  4,  ∗  5,  ∗  6,  ∗  7,  ∗  8,  ∗  17) was performed. In addi-
tion, platelet function was measured by aggregom-
etry, VerifyNow P  2  Y  12   assay, and VASP assay at 
pre-dose, 8 hours post-loading, and during mainte-
nance. There was no signiﬁ  cant effect of the geno-
type on platelet function during aspirin therapy 
alone. On the other hand, irrespective of the 2C19 
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employed, subjects on ticagrelor showed a lower 
platelet reactivity than did those on clopidogrel 
(  P        0.01). This is consistent with a genotype-
independent better pharmacodynamic effect of 
ticagrelor as compared to clopidogrel (57). 
  The DISPERSE trial (200 subjects with stable 
atherosclerotic disease) (54) showed ticagrelor 
(100 mg/b.i.d., 200 mg/b.i.d., or 400 mg/d) to inhibit 
platelet aggregation more rapidly and effectively and 
with less variability than clopidogrel (75 mg/d). The 
DISPERSE-2 trial (58) (990 NSTEMI patients) 
showed that ticagrelor, added to standard medical 
treatment, has a safety proﬁ  le similar to clopidogrel 
with a better proﬁ   le as to the incidence of AMI, 
silent AMI, severe recurrent ischemia, stroke, and 
death. However, the study was not powered to 
detect differences in efﬁ  cacy end-points (size), nor 
was the duration of the drug exposure appropriate 
(52). 
  The PLATO trial was a phase III, multicenter, 
randomized, double-blind, double-dummy study 
that evaluated the efﬁ  cacy and safety of ticagrelor 
and of clopidogrel in lowering the risk of vascular 
events in more than 18,000 NSTEMI or STEMI 
patients (59). Within 24 hours after a diagnosis 
of ACS, the patients were randomized to receive 
ticagrelor 90 mg/twice daily or clopidogrel 75 mg 
once daily for 6  –  12 months. Before starting the 
maintenance dose, each subject received a loading 
dose of 180 mg ticagrelor or 300 mg clopidogrel, 
depending on the group of randomization. All sub-
jects received concomitant treatment with aspirin 
75  –  100 mg/day. The primary outcome of the study 
was the time to the ﬁ  rst occurrence of cardiovascu-
lar or cerebrovascular death, non-fatal MI, or non-
fatal stroke. The primary safety outcome was the 
time to the ﬁ  rst occurrence of any major bleeding 
event. At 12 months, the primary end-point occurred 
in 9.8% of patients receiving ticagrelor as compared 
with 11.7% of those receiving clopidogrel (HR 0.84; 
95% CI 0.77  –  0.92;   P       0.001). Similar ﬁ  gures were 
achieved by evaluating the rate of the primary out-
come at 30 days (4.8% for ticagrelor group versus 
5.4% for clopidogrel group;   P       0.045). The rate of 
death from any cause was also reduced with ticagre-
lor (4.5% versus 5.9% with clopidogrel;   P       0.001). 
Major, life-threatening, or fatal bleedings did not 
differ between those on ticagrelor and on clopi-
dogrel (11.6% and 11.2%, respectively;   P       0.43), 
nor did CABG-related major bleeding, although 
ticagrelor patients were allowed to undergo CABG 
earlier (24  –  72 hours), after withdrawing from the 
study drug, as compared to those on clopidogrel 
(5 days). However, vis-  à  -vis fewer fatal bleeding 
episodes of other types, a higher rate of higher 
major bleeding not related to coronary artery bypass 
grafting (4.5% versus 3.8%;   P       0.03),  including 
fatal intracranial bleedings, were detected in subjects 
on ticagrelor. Secondary end-point evaluation showed 
signiﬁ   cant differences in the rates of myocardial 
infarction (5.8% in the ticagrelor group versus 6.9% 
in the clopidogrel group;   P        0.005) and of death 
from vascular causes (4.0% versus 5.1%;   P       0.001), 
but not of stroke (1.5% versus 1.3%;   P       0.22). 
  More patients in the ticagrelor group discontin-
ued the study drug due to adverse events compared 
to the clopidogrel group (7.4% versus 6.0%; 
  P       0.001). A signiﬁ  cantly higher reversible increase 
in serum uric acid and creatinine was found in 
subjects receiving ticagrelor. Dyspnea, nausea, 
hypotension, and asymptomatic ventricular pauses 
were more frequent in the ticagrelor group, maybe 
because of an adenosine-mediated response (60). 
Thus, the use of ticagrelor should be evaluated with 
caution in patients with hyperuricemia, bradyar-
rhythmias without pacemakers, and syncope and in 
those at high risk of bleeding (e.g. elderly, low body-
weight, renal dysfunction) and avoided in patients 
with history of stroke (61). Of interest, in the ONSET/
OFFSET study, 123 patients with stable coronary 
artery disease receiving aspirin (75  –  100 mg/d) 
received on top ticagrelor (180-mg load, 90-mg b.i.d. 
maintenance dose (  n        57)), clopidogrel (600-mg 
load, 75-mg/d maintenance dose (  n       54)), or placebo 
(  n        12) for 6 weeks. Ticagrelor achieved a more 
rapid and greater platelet inhibition (evaluated with 
20   μ  mol/L ADP) than did high-loading-dose clopi-
dogrel. In addition, a faster offset occurred with 
ticagrelor than with clopidogrel (4  –  72-hour slope 
(% inhibition of platelet aggregation/h) –1.04 versus 
–0.48;   P        0.0001) (62). To evaluate further the 
safety and efﬁ  cacy parameters, in a phase III study 
(NCT01294462) 90 mg/twice daily ticagrelor (on 
top of 100 mg aspirin) will be compared to 
75 mg clopidogrel (on top of 100 mg aspirin as well) 
in ACS subjects with a planned PCI. The safety 
outcome will be evaluated by measuring the time to 
ﬁ  rst occurrence of any major bleeding event. The 
time to ﬁ  rst occurrence of the composite of death 
from any vascular cause (myocardial infarction and 
stroke) will also be measured. 
  The study is expected to enroll 800 subjects, and 
the estimated study completion date is August 2012. 
In addition, a randomized phase III PEGASUS 
trial (NCT01225562), on an expected number of 
21,000 subjects with a history of myocardial infarc-
tion, will evaluate the efﬁ  cacy of ticagrelor (90 or 
60 mg/twice daily) compared to placebo on top of 
aspirin (100 mg) in the prevention of the compos-
ite end-point of cardiovascular death, non-fatal MI, 
or non-fatal stroke. The end of the study is expected 
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  Elinogrel 
  Elinogrel (PRT128) is a direct, reversible P  2  Y  12   
inhibitor available in both oral and intravenous for-
mulations. In a randomized, double-blind, placebo-
controlled trial (63) in which single intravenous 
doses (1  –  40 mg) were administered, elinogrel yielded 
a dose-dependent, complete inhibition of ADP-
induced aggregation. All doses of elinogrel were well 
tolerated, with no serious adverse events observed.     
  Sarpogrelate 
  Sarpogrelate is a selective inhibitor of 5-HT platelet 
receptors. In the S-ACCESS trial (64), 1,510 patients 
with recent cerebral infarction were randomly 
assigned to receive either sarpogrelate (100 mg t.i.d.) 
or aspirin (81 mg/day). Mean follow-up was 1.59 
years, with the recurrence of a cerebral infarction 
as primary efﬁ   cacy end-point. Clusters of serious 
vascular events (stroke, acute coronary syndrome, 
or vascular death) were secondary end-points. The 
aim of the primary efﬁ  cacy analysis was the non-
inferiority of sarpogrelate with respect to aspirin, 
the upper limit of the 95% CI of the hazard ratio 
for the recurrence of cerebral infarction not exceed-
ing 1.33. Cerebral infarction recurred in 72 patients 
in the sarpogrelate group and in 58 in the aspirin 
group (HR 1.25; 95% CI 0.89  –  1.77;   P       0.19).  A 
serious vascular event occurred in 90 and in 85 
patients, respectively (HR 1.07; 95% CI 0.80  –  1.44; 
  P        0.65). The overall incidence of bleeding events 
was 89 (11.9%) and 131 (17.3%), respectively 
(  P       0.01).    
  DZ-697b 
  DZ-697b inhibits collagen and ristocetin-mediated 
platelet adhesion and aggregation and does not 
require metabolization to generate its active com-
pound (65). The antithrombotic effect and the bleed-
ing time prolongation of three DZ-697b doses were 
compared with 300 mg clopidogrel in 20 healthy 
subjects randomized to a single oral dose of DZ-697b 
(60, 120, and 360 mg) or clopidogrel (300 mg). 
DZ-697b (120 mg) showed antithrombotic effects 
comparable to 300 mg clopidogrel, with signiﬁ  cantly 
reduced bleeding time prolongations.     
  Atopaxar (E5555) 
  Atopaxar (E5555) is a small molecule, 1-(3-  tert-
butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-
  7-fluoro-1-imino-1,3-dihydro-2  H-isoindol-2yl) 
ethanone   hydrobromide that acts as PAR-1 antagonist. 
In healthy volunteers, E5555 showed antiplatelet 
effects without increasing bleeding times. Two ran-
domized, double-blind, placebo-controlled phase II 
clinical trials (J-LANCELOT) (66) have assessed 
the safety and tolerability of atopaxar in addition 
to standard therapy in patients with ACS or high-
risk coronary artery disease. In addition to aspirin, 
patients received atopaxar (50 mg, 100 mg, or 
200 mg) or placebo once daily for 12 or 24 weeks. 
All atopaxar doses tested achieved a signiﬁ  cant level 
of platelet inhibition with no increase in severe 
bleeding episodes. The rate of major cardiovascular 
adverse events in the atopaxar group was similar to 
placebo (ACS 6.6% and 5.0% in placebo or E5555, 
respectively,   P        0.73; CAD 4.5% placebo versus 
1.0% E5555,   P       0.066).    
  Vorapaxar 
  Vorapaxar (SCH 530348) is an orally active and 
reversible agent belonging to the class of thrombin 
receptor antagonists (TRAs). Vorapaxar blocks the 
platelet PAR-1 receptor, inhibiting thrombin-induced 
activation and aggregation of platelets without affect-
ing thrombin-induced ﬁ   brin production. Phase I 
study data showed a signiﬁ  cant dose-related inhibi-
tion of platelet aggregation with      90% inhibition at 
1 h, lasting at least 72 h in the absence of signiﬁ  cant 
adverse events (67). The TRA-PCI (68), a random-
ized, double-blind, multicenter phase II study, was 
designed to assess tolerability and safety of an oral 
loading dose of vorapaxar (10 mg, 20 mg, or 40 mg) 
in patients undergoing coronary angiography with 
planned PCI. In addition to the standard of care 
(aspirin      clopidogrel), those who subsequently 
underwent PCI received an oral maintenance dose 
(0.5 mg, 1.0 mg, or 2.5 mg/day) of vorapaxar or 
placebo for 60 days. The primary end-point was the 
incidence of clinically signiﬁ   cant major or minor 
bleeding according to the TIMI scale. In spite of the 
limited time of observation (60 days) versus the very 
long half-life (100  –  360 h) of vorapaxar, no difference 
in the primary end-point of major or minor bleeding 
has been found (2%, 3%, 4% in the three loading 
dose groups versus 3.3% in placebo group;   P       0.57). 
Nor were signiﬁ  cant differences in major cardiovas-
cular events observed in the two groups. Platelet 
function testing showed a very potent and sustained 
effect with the 40-mg loading dose and the 2.5-mg 
maintenance dose. In a subgroup of subjects under-
going coronary bypass surgery while under vora-
paxar, there was no evidence of increased bleeding, 
suggesting that PAR-1 blockade during cardiopul-
monary bypass may   ‘  preserve  ’   normal hemostasis 
(69). In a phase II study (70), 117 NSTEMI patients 
undergoing non-urgent PCI have been randomized 
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therapy (aspirin        ticlopidine) and heparin, two dif-
ferent dosages of vorapaxar (20 mg or 40 mg loading 
dose, followed by 1 mg/d or 2.5 mg/d maintenance 
dose) or placebo. While TIMI major and minor 
bleedings were similar between the different treat-
ment arms (14% versus 10%), peri-procedural AMI 
was signiﬁ   cantly lower in treated patients (16.9% 
versus 42.9 in the placebo group %;   P       0.013). 
  Two large multicenter, international, prospective, 
double-blind, placebo-controlled phase III clinical 
trials were designed to establish the potential role 
of vorapaxar in treatment of CAD patients. TRA  ∗   
CER (71) is a prospective, randomized, double-blind, 
multicenter phase III trial designed to determine 
whether vorapaxar (40-mg loading dose, followed by 
2.5 mg daily for at least 1 year) can lead to further 
reduction in ischemic events when added to stan-
dard medical treatment in NSTEMI patients. As an 
estimate, 19,000 subjects are required to achieve 
adequate power. Primary composite end-point is 
the effect on cardiovascular death, AMI, stroke, 
recurrent ischemia with hospitalization, urgent 
PCI, and bleeding. 
  TRA 2  °  P-TIMI 50 (72) will evaluate the efﬁ  cacy 
and safety of vorapaxar during long-term treatment 
of patients with established atherosclerotic disease 
receiving standard therapy (up to 27,000 patients). 
The study targeted patients with a documented his-
tory of AMI or stroke within 2 weeks to 12 months 
before the time of inclusion. Patients with peripheral 
artery disease (PAD) are eligible for inclusion if 
they have intermittent claudication in conjunction 
with an ankle-brachial index        0.85 or previous 
revascularization for limb ischemia. Participants are 
randomized to receive vorapaxar (2.5 mg daily) or 
placebo in addition to standard therapy for at least 
1 year. The primary composite end-point is cardio-
vascular death, AMI, stroke, or urgent coronary 
revascularization, whereas the evaluation of long-
term safety includes bleeding events deﬁ  ned by the 
GUSTO and TIMI criteria.       
  Future antiplatelet drugs 
  In addition to the antiplatelet drugs reported above, 
there is a continuous effort to identify newer targets 
toward which to direct pharmacological strategies. 
  Gas6 (growth arrest-speciﬁ  c gene 6), a member 
of the family of vitamin K-dependent proteins, is 
stored in platelet   α   granules and is released upon 
activation (73). Although it has a 44% sequence 
homology with protein S, it does not show any anti-
coagulant activity (74). Being a growth factor-like 
molecule, as it interacts with receptor tyrosine kinases 
(RTKs) of the Tyro3, Axl, and MerTK (TAM) 
family, Gas6 employs a unique mechanism of action, 
interacting through its vitamin K-dependent Gla 
module with phosphatidylserine-containing mem-
branes and through its carboxy-terminal LG domains 
with the TAM membrane receptors. Studies indicate 
an association between Gas6 and stroke. Inhibition of 
Gas6 function can be achieved by Gas6-neutralizing 
antibodies, by proteases cleaving the extracellular 
domain of Gas6 receptors, or by inactivation of 
RNA for Gas6 or Gas6 receptors. Antibodies to the 
carboxy-terminal part of Gas6, responsible for the 
binding to its receptors, inhibit the aggregation of 
human platelets induced by ADP (75). 
  Matrix metalloproteinases (MMPs) are involved 
in tissue remodeling and in the progression of athero-
sclerosis (76). Human platelets contain MMP-2 in 
their cytosol and release them upon aggregation (77). 
Active MMP-2, potentiating phosphoinositide-3 
kinase activation, ampliﬁ   es platelet aggregation 
induced by a variety of agonists in an aspirin- or 
ADP-receptor antagonist-independent fashion (78). 
MMP-2-neutralizing antibodies have shown protec-
tive effects in hearts exposed to ischemia  –  reperfusion 
injury (79). MMP-2 gene-silencing techniques (80) 
may be exploited to gain cell-selective MMP-2 
inhibition. 
  The CD40 ligand (CD40L; CD154) is a trans-
membrane protein expressed on the surface of acti-
vated platelets. Following its exposure, an exodomain 
(soluble CD40 ligand, sCD40L) is released and 
binds to integrin   α    IIb    β    3   on activated platelets, thus 
promoting thrombus stabilization (81). Therapeutic 
targeting of the CD40-CD40L axis using humanized 
anti-CD40L antibodies has already been attemp-
ted (82). Shedding of sCD40L from the surface of 
activated platelets can be prevented by an anti-
CD40L antibody (G28-5). This may reduce plasma 
concentrations of sCD40L and, in turn, blunt plate-
let reactivity (83). In addition to the production by 
platelets, PGE  2   is also produced by other cells in 
blood, including monocytes. Low concentrations of 
PGE  2   potentiate platelet aggregation by priming 
protein kinase C activation and by inhibiting ade-
nylylcyclase. The facilitating effects of PGE  2   on 
platelets are mediated by EP3 (84,85). In animal 
studies, DG041, a novel ﬁ  rst-in-class antagonist of 
EP3, effectively inhibits platelet aggregation without 
increasing the bleeding time (86). In a phase II trial 
in patients with peripheral arterial disease, DG041 
was found to reduce platelet activation (87).     
  Conclusions 
  Major limitations of current antiplatelet drugs 
include risk of bleeding, signiﬁ  cant interindividual 
variability in the response, and extended duration 
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hemostasis or emergency surgery arises. Newer anti-
platelet drugs have addressed some but not all these 
limitations. Dual antiplatelet treatment has only 
been efﬁ   cacious in acute coronary syndromes. In 
addition, newer thienopyridines did not show advan-
tages over and above those of ticlopidine or clopi-
dogrel as to reduction of stroke. Because of its 
pharmacodynamic characteristics, prasugrel is more 
efﬁ  cacious in preventing ischemic events in patients 
with ACS undergoing PCI, but with increased bleed-
ing complications. The same concept is true for 
ticagrelor. Platelet activation by thrombin is distinct 
and appears to be less important for hemostasis than 
ﬁ   brin generation (preclinical data). Accordingly, 
inhibition of PAR-1 function rather than inhibition 
of ﬁ  brin generation or activity may provide a newer 
strategy for treatment of thrombotic disorders 
in humans (88). Individual bleeding risk, however, 
has to be further deﬁ  ned, as this would be the ﬁ  rst 
antiplatelet drug in which a greater efﬁ  cacy is not 
associated with a worse safety (greater bleeding 
tendency). 
  A concerted effort that takes into consideration 
clinical, genetic, and laboratory information repre-
sents a major direction to be pursued in order 
to tailor the therapeutic approach for individual 
patients. The results of on-going clinical trials and 
the identiﬁ  cation of further potentially useful targets 
for antiplatelet treatment (87) will hopefully help 
address this issue.               
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  Note 
While this manuscript was under revision, results 
from LANCELOT-CAD were published (Circulation. 
2011;123:1854–1863). In this study patients with a 
history of high-risk CAD were randomized to receive 
50, 100, or 200 mg daily atopaxar or matching 
placebo for 24 weeks and followed up for an addi-
tional 4 weeks. Although no difference was found as 
to major bleeding events, overall bleeding incidence 
(key safety end point) showed a dose-dependent 
trend in the atopaxar arm as compared with placebo 
by CURE criteria (p for trend0.01) but not by 
TIMI criteria (p for trend0.07). As to the major 
adverse cardiac events occurrence (secondary end 
points), no signiﬁ  cant difference was found between 
the atopaxar treatment arms and placebo (2.6% vs 
4.6%; p0.20). In addition, a transient elevation 
in liver transaminases and dose-dependent QTc 
prolongation without apparent complications were 
observed in higher-dose atopaxar treatment groups.
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